Vanda Pharmaceuticals Inc. (VNDA)
Nasdaq · Healthcare · Biotechnology
$4.58−1.08%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $277M
- Forward P/E
- 22.9
- 52-week range
- $4.27 – $9.94
- 52-week change
- −12.97%
- EPS (trailing)
- −$4.63
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $216M (+8.72%)
- Net income
- −$221M
- Operating margin
- −70.0%
- Diluted EPS
- −$3.74
- Free cash flow
- −$110M
From the company’s annual report on SEC EDGAR.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis.
Headquarters: Washington, United States · 533 employees · vandapharma.com